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Background: Distinguishing between multiple primary lung cancers and metastatic tumors is often difficult when
the tumor histology is same. Since genomic instability is a common feature of cancer, we hypothesized that
independently arising neoplasms in an individual patient would exhibit measurable genomic variation, enabling
discrimination of tumor lineage and relatedness. The feasibility of analyzing genomic instability expression profiles
to distinguish multiple primary lung cancers from metastatic tumors was evaluated.
Methods: This study enrolled 13 patients, with multiple primary lung cancers demonstrating with the histology,
who underwent surgery between April 2003 and December 2012 at the Department of the Thoracic Surgery at
West China Hospital in Sichuan province of China and 10 patients who were diagnosed as metastasis disease
during the same period for comparison purposes. Genomic DNA from lung cancers from individual patients was
analyzed by six microsatellites (D2S1363, D6S1056, D7S1824, D10S1239, D15S822, and D22S689) with PCR to identify
discordant allelic variation. The experiments were approved by the West China Hospital Ethics committee (No.2013
(33)) and all patients agreed to participate in the study and signed an informed consent form.
Results: All of the 10 patients with distant metastasis showed a consistent consequence that we called “unique
trend” between primary tumor and distant metastasis. The “trend” is representive in this study, which means that all
alleles corresponding to six microsatellite markers were detected in DNA from primary tumors but were reduced or
not observed in DNA from metastatic tumors. In the group of synchronous lung tumor with different histological
types, the result showed a “contradictory trend”. Some alleles were detected in DNA from primary tumors but were
reduced or not observed in DNA from metastatic tumors and other alleles corresponding to six microsatellite
markers were detected in DNA from metastatic tumors but were reduced or not observed in DNA from primary
tumors. In the third group (synchronous lung tumor with same histological types), 2 of 8 patients showed “unique
trend” and the others showed “contradictory trend”.
Conclusions: With polymorphic microsatellite markers, the “unique trend” that represents metastasis cancers and
the “contradictory trend” that represents primary multiple tumors are useful in the diagnosis between tumors found
at the same time in the pulmonary even diagnosed with the histopathological evaluation from a single patient.
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Surgery-based multi-discipline treatment has signifi-
cantly prolonged the survival for patients with lung can-
cer, and at the same time increased risk for multiple
primary cancers after the first treatment. The incidence
of multiple primary lung cancers has been reported to
range from 0.7% to 15% of patients with lung cancer
[1-5]. Dual primary lung cancer, also known as multiple
primary lung cancer (MPLC), refers to two or more pri-
mary cancers in different sites of one or both lungs, with
either consistent or different histology but no association
between two cancers. Based on the time when the tu-
mors are identified, the disease can be classified as syn-
chronous or metachronous [6]. At present, diagnostic
criteria are simply based on pathology and radiology,
the majority of multiple primary lung cancers are
misdiagnosed as metastatic cancer in the issue. They,
however, present as a solitary mass in the majority of cir-
cumstances [7], raising the possibility of a metachronous
second primary lung cancer. Especially, when patients
develop multiple, morphologically similar lung cancer,
the clinical diagnosis becomes critical for the selection
of an appropriate treatment (surgery for multiple pri-
mary tumors versus systemic chemotherapy for solitary
pulmonary metastatic disease). In the absence of carcin-
oma in situ, the morphologic similarity between the first
and the second lung neoplasm can make it impossible to
make the diagnostic distinction between metachronous
primary neoplasms and solitary pulmonary metastasis,
while it is also difficult to make the diagnostic distinc-
tion between synchronous primary lung cancer and the
metastasis if they have the similar morphology. Thus,
traditional histopathological assessment of neoplasms of
the aerodigestive tract cannot definitively distinguish
multiple primary cancers from metastatic disease when
solitary, histologically similar cancers arise synchron-
ously or metachronously in an individual patient. Com-
parison of the histology of both neoplasms for similarity
or difference in histologic grade may suggest a common
or independent origin, but it is recognized that tumor
grade can show regional heterogeneity in an individual
neoplasms, and that metastases may not always display
the same grades as their parent primaries [8].
Synchronous lung cancers are rare and rather little is
known as for their genetic basis [9]. The incidence of
synchronous lung carcinomas is variably reported be-
tween 1% and 16% [10]. The 5-year survival of patients
with synchronous multiple primary lung cancers has
been reported to range from 0% to 44% despite an early
diagnosis [11-14].
Recent advances in molecular biology have provided
several markers that can be used for clonal analysis. As gen-
omic instability represents one of the hallmarks of human
cancer [15-17], the multiple, independently developingneoplasms in an individual patient will possess measurable
genomic variation that can be analyzed to generate unique
molecular signatures that reflect tumor lineage and related-
ness. Allelic variation between neoplasms often reflects
accumulation of differential chromosomal deletion events.
These chromosomal deletions are tolerated (non-lethal),
but distinct from the molecular alterations that drive
tumorigenesis, which will be common to most/all tumors
of a specific type. Comparison of molecular signatures
between two (or more) tumors from a single individual
facilitates identification of common and unique genetic
alterations [8]. These genetic alterations can be detected
by polymerase chain reaction (PCR)-based microsatellite
analysis, by DNA sequencing, and occasionally by
immunohistochemistry.
In this study, we examined 18 patients with synchron-
ous multiple lung tumors utilizing a PCR-based ap-
proach to screen polymorphic microsatellite markers for
variation in allele numbers. The results of this study
demonstrate that molecular methods are useful for
distinction of second primary neoplasms from solitary
pulmonary metastasis in patients.
Methods
Patients and clinical features
Among the consecutive patients with primary lung
cancer who had undergone a surgical resection between
April 2003 and December 2012 at the Department of
the Thoracic Surgery at West China Hospital, Sichuan,
China, 13 patients were diagnosed with multiple primary
lung cancers according to criteria proposed by Martini
and Melamed [18]. Cases from patients with multiple
lung cancers were retrieved and carefully reviewed. They
were classified as synchronous (diagnosis of both tumors
at the same time based solely on the traditional histo-
pathological evaluation) tumors with the same histo-
logical type or not. Of these, 8 patients were diagnosed
as having multiple primary lung cancers with the same
histological types, and 5 patients were diagnosed with
different histological types. 10 cases of pulmonary
tumors with metastasis (to brain,Sternum or adrenal
gland) were selected for comparison. All patients were
followed up and the status recorded as alive or dead. In
each case of the synchronous multiple primary lung
cancers; the first tumor was designated as Tumor 1 (T1),
while subsequent tumors were designated as Tumor 2
(T2). When multiple tumors were surgically removed
from a given patient at the same time, tumor designa-
tions were assigned arbitrarily. While the multiple neo-
plasms from each patient were designated T1 and T2,
the actual temporal order of appearance and lineage
relationships between tumors (if any) were not known.
Thus, in each patient these neoplasms could represent
(i) multiple primary lung cancers, or (ii) primary lung
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nosis, sex, site of tumor, histology, and the status of
following up for each patient are given in Table 1. The
experiments were approved by the West China Hospital
Ethics committee (No.2013 (33)) and all patients agreed
to participate in the study and signed an informed
consent form.
Preparation of genomic DNA
Recut sections stained with hematoxylin and eosin (H&E)
were used to identify regions of well-preserved tumor tissue
containing ≥90% tumor. Tumor tissues from 3–5 unstained
5 μm sections were dissected away from tumor stroma and
using a sterile scalpel for each case and collected in 600 μl
of xylene. Deparaffinization was achieved by incubating for
5 min in xylene, followed by centrifugation at 14,000× g for
2 min to collect deparaffinzed tissues. The tissue pellet was
resuspended in 600 μl of 95% ethanol, washed for 5 min,
and centrifuged at 14,000× g for 3 min. The resulting tissue
pellet was dried and DNA isolated using the Paraffin-
embedded tissue genomic DNA extraction kit according to
the manufacturer’s protocol (Bioteke Corporation, Beijing).
Microsatellite PCR analysis
Genomic DNA collected from tumor samples were exam-
ined for 6 polymorphic microsatellite markers that are the
most representative in the detection of measurable genomic
variation and displayed high reproducibility in a PCR-based
assay, including: D2S1363 (2q34), D6S1056 (6q23.2),
D7S1824 (7q33), D10S1239 (10q24.3), D15S822 (15q12),
and D22S689 (22q12.1). Information concerning these
markers and primer sequences is available on the Genome
Database (http://www.gdb.org/) and the NCBI genome
database (http://www.ncbi.nlm.nih.gov/). The oligonucleo-
tide primers corresponding to each microsatellite marker
(MapPairs™primers) were purchased from Sangon Biotech
(Shanghai) Co., Ltd. For PCR, the reaction samples were
each prepared to a total volume of 25 μL as follows:
12.5 μL PCR Mix (2X) (PCR Master Mix 2X, Thermo
SCIENTIFIC), 1 μL each primer, 1 μL template DNA, and
9.5 μL nuclease-free water. Amplifications were carried
out in a Perkin Elmer Thermocycler using a step–cycle
program consisting of 39 cycles of 95°C for denaturing
(30 seconds), 55°C for annealing (30 seconds), and 72°C for
extension (1 min). PCR products were fractionated on 6%
polyacrylamide gels containing Tris–borate/EDTA (pH 8.0)
and visualized by ethidium bromide staining. PCR reactions
that did not produce detectable amplified products were
re-amplified to confirm a negative result.
Results
Molecular signatures were generated for each of 46 tu-
mors using 6 polymorphic microsatellite markers. These
46 tumors represent either multiple primary cancers orprimary cancer and metastatic disease from 13 patients
(n = 26), as well as a known outgroup control primary
lung cancer with its metastasis (n = 20). One objective of
the current investigation was to identify microsatellite
markers that are useful in the detection of measurable
genomic variation (allelic imbalance or allelic variation)
among multiple tumor-derived DNAs from individual
patients. Of the 6 microsatellite markers evaluated, all
detected allelic imbalance or allelic variation among all
tumors from at least one patient. The 6 microsatellite
markers examined identified allelic variation in 17–57%
of patients, and the majority of microsatellite markers
(13/23, 57%) detected allelic differences in tumors. These
observed allelic differences correspond to evidence of
dissimilarity among the tumors in question.
Analysis of primary and metastatic tumors
To verify that microsatellite PCR could detect a lineage
relationship between tumor pairs, we first analyzed the
relationship between primary and metastatic tumors.
Ten pairs of tumors were chosen, each consisting of a
primary lung tumor and a metastatic tumor to the brain,
the sternum or the left adrenal gland. (Table 2) Lineage
relationships for each of these tumor pairs were deter-
mined by molecular analysis. For example, alleles corre-
sponding to microsatellite markers D2S1363, D10S1239,
and D15S822 were detected in DNA from T1 of Patient
1, but were not observed in DNA from T2 (Table 2).
Likewise, alleles corresponding to microsatellite markers
D10S1239 and D22S689 were observed in T1 of Patient
3, but were not detected in T2. Similar results were
obtained for Patients 4, 8 and 10. In the case of Patient
5 and 9, the allelic variation was only observed at
D22S689 or D15S822. Because the tumor designations
were assigned arbitrarily when multiple tumors were
surgically removed from a given patient at the same
time, Patient 2 and 7 represented inverted consequence
in the Table 2. However, we understand that the T2 of
Patient 2 and 7 were primary tumors and T1 were meta-
static tumors. In the case, Patient 6, the two neoplasms
share common allelic patterns only for 1 microsatellite
marker at D7S1824, but show differing allelic patterns
for 5 microsatellite markers at D2S1363, D6S1056,
D10S1239, D15S822 and D22S689 (see Figure 1 and
Table 2). The molecular signatures for these two tumors
are notably different and the pattern of allelic variation
presented allelic loss in 5 microsatellite markers direc-
tion in T2 of the patient. All of these support the hy-
pothesis that the lung cancer was the primary neoplasm
that gave rise to the brain, sternum or left adrenal gland
metastasis. Further, these molecular data indicate that
the metastatic cancer in the brain, sternum or left ad-
renal gland could not have given rise to the lung cancer.
These observations confirm that microsatellite PCR has
Table 1 Clinical and pathologic data of all patients
Patients designation Age Sex Site of tumor Histology Follow up
Metastatic carcinomas originating in the lung Patient1 T1 54 M RLL squamous carcinoma Alive
T2 Sternum squamous carcinoma
Patient2 T1 59 M Brain adenocarcinoma Dead
T2 RUL adenocarcinoma
Patient3 T1 70 M LUL squamous carcinoma Dead
T2 Brain squamous carcinoma
Patient4 T1 45 F LLL adenocarcinoma Dead
T2 Brain adenocarcinoma
Patient5 T1 39 F RLL adenocarcinoma Alive
T2 Brain adenocarcinoma
Patient6 T1 58 F RUL adenocarcinoma Alive
T2 Rib adenocarcinoma
Patient7 T1 56 M Brain adenocarcinoma Dead
T2 RML adenocarcinoma
Patient8 T1 55 M LUL squamous carcinoma Alive
T2 Left adrenal gland squamous carcinoma
Patient9 T1 46 M LLL adenocarcinoma Alive
T2 Brain adenocarcinoma
Patient10 T1 56 M LUL squamous carcinoma Alive
T2 Brain squamous carcinoma
Synchronous lung tumor with different histological types Patient1 T1 71 M RUL adenocarcinoma Dead
T2 RLL squamous carcinoma
Patient2 T1 47 M RLL squamous carcinoma Alive
T2 RUL adenocarcinoma
Patient3 T1 72 M LLL adenocarcinoma Dead
T2 LUL squamous carcinoma
Patient4 T1 59 M RUL adenocarcinoma Alive
T2 RLL squamous carcinoma
Patient5 T1 74 M RUL adenocarcinoma Alive
T2 RLL squamous carcinoma
Synchronous lung tumor with same histological types Patient1 T1 53 M RML adenocarcinoma Dead
T2 RUL adenocarcinoma
Patient2 T1 47 M LLL adenocarcinoma Dead
T2 LUL adenocarcinoma
Patient3 T1 52 F RUL adenocarcinoma Alive
T2 RLL adenocarcinoma
Patient4 T1 70 F RLL adenocarcinoma Alive
T2 RUL adenocarcinoma
Patient5 T1 73 M LLL squamous carcinoma Alive
T2 LUL squamous carcinoma
Patient6 T1 65 M RML squamous carcinoma Alive
T2 RLL squamous carcinoma
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Table 1 Clinical and pathologic data of all patients (Continued)
Patient7 T1 55 M LLL squamous carcinoma Alive
T2 LUL squamous carcinoma
Patient8 T1 69 M RUL adenocarcinoma Dead
T2 RLL adenocarcinoma
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lineage among neoplasms in an individual patient.
Analysis of synchronous lung tumor with different
histological types
Five cases of synchronous tumors (Table 2) of the lung
were also studied for molecular analysis. In the typical
case of Patient 3, the observed allelic variation at
D2S1363 and D7S1824 suggest that T2 could be derived
from T1, consistent with metastatic disease (see Figure 2
and Table 2). However, the allelic variation noted at
D6S1056 and D10S1239 contradicts this possible lineage
relationship. Thus, the collective allelic variation involv-
ing 4 microsatellite markers suggests that neoplasms
from Patient 3 represent independently arising primary
lung cancer. In the other patients, alleles corresponding
to microsatellite markers D10S1239 were amplified in
DNA from T2 of Patient 1, but were not observed in
DNA from T1. However, in the same patient, D22S689
were detected in DNA from T1 of Patient 1, but were
not found in DNA from T2. Similar results were
obtained for Patients 2, 4 and 5. However, this conclu-
sion is made with less confidence when the numbers of
discordant changes are this few. Given that there is con-
cern about the effects of intra-tumor heterogeneity on
this type of analysis, increased numbers of microsatellite
markers (and observations of allelic variation) might be
required to draw clear conclusions in some cases.
Analysis of synchronous lung tumor with same
histological types
Eight cases presented with synchronous multiple tumors
of the lung were also studied for molecular analysis. The
microsatellite PCR results for each of these patients are
given in Table 2.
Patient 5 was diagnosed with adenocarcinoma of the
right upper lobe and right lower lobe at the same time.
Given the histopathology and interval for these neo-
plasms, conventional staging criteria would classify one
of the lung cancer as a metastatic lesion derived from
the other one. However, molecular analysis of these
tumors identified discordant allelic variations involving 3
different microsatellite markers, 2 of which are gains of
alleles, arguing that these cancers arose independently.
Alleles for D7S1824 was detected in the T1 that were
not observed in the subsequent lung tumor (T2). In con-
trast, alleles corresponding to D15S822 and D22S689were detected in the lung cancer (T2) that were not ob-
served in the T1. These mutually exclusive allelic losses
strongly suggest that these neoplasms are not related.
Thus, the lung cancer in this patient represents a second
primary carcinoma rather than a solitary metastatic
lesion derived from the other one. Likewise, alleles
corresponding to microsatellite markers D2S1363 was
observed in T1 of Patient 4, but was not detected in T2.
At the same time, microsatellite markers D10S1239 was
observed in T2, but was not detected in T1. The results
of two patients are similar to the synchronous lung
tumor with different histological types and suggest that
the synchronous lung tumors in this patient are not
related and represent multiple primary tumors.
Patient 1 was diagnosed as adenocarcinoma of the
right middle lobe and right upper lobe. In this case, the
molecular evidence was based upon concordant results
with D6S1056, D15S822 and D22S689. Alleles corre-
sponding to microsatellite markers D6S1056, D15S822
and D22S689 were observed in T1, but were not
detected in T2. The results strongly suggest that the T1
has given rise to T2 and suggest that the T1 metasta-
sized to the T2, based upon gain of alleles for these
markers.
Molecular analysis of Patient 2 provided a clear ex-
ample of a patient with clonally-related neoplasms even
it was classified as synchronous lung tumor, where the
evidence suggest that the T1 metastasized to the T2. In
this case, microsatellite markers D2S1363, D6S1056,
D15S822 and D22S689 were detected in DNA from T1,
but these markers were not found in DNA from T2.
Like Patient 4 and 5, either primary tumor in Patient 6
and 8 could have given rise to the other lung cancer (in
the case of metastatic disease), or it could represent a
primary synchronous cancer. However, the results with
D6S1056 and D10S1239 suggest that T1 have given rise
to T2, based upon gain of alleles for these markers in
the T1. These observations argue that the lung cancer in
patient 6 and 8 represent a metastatic disease rather
than primary synchronous lung cancer.
Patient 3 and 7 was diagnosed as the synchronous
lung tumor with same histological types according to
the conventional clinical staging criteria. The goal was
to determine if T1 did not relate to T2. Alleles for
D6S1056 or D22S689 were detected in the DNA from
the T1 that was not observed in the T2 (Table 2), con-
sistent with the suggestion that the T2 represents a
Table 2 Microsatellite marker of all tumors
Patient designation D2S1363 D6S1056 D7S1824 D10S1239 D15S822 D22S689
Primary and metastatic tumors Patient1 T1 + + + + + -
T2 - + + - - -
Patient2 T1 - - - - ++ -
T2 - + + + ++ -
Patient3 T1 + ++ + ++ + +
T2 + ++ + + + -
Patient4 T1 + + + ++ + -
T2 + + + - - -
Patient5 T1 + + + + ++ ++
T2 + + + + ++ -
Patient6 T1 ++ + + ++ ++ +
T2 + - + - - -
Patient7 T1 - - - + - -
T2 ++ - + ++ - -
Patient8 T1 + ++ + + + -
T2 + - + + - -
Patient9 T1 + ++ + ++ + -
T2 + ++ + ++ - -
Patient10 T1 ++ ++ + + - -
T2 - - + + - -
Synchronous tumors with different histological types Patient1 T1 + + + - - +
T2 + + + ++ - -
Patient2 T1 ++ ++ + ++ ++ -
T2 ++ +++ + + ++ -
Patient3 T1 ++ - + - ++ -
T2 - + - + ++ -
Patient4 T1 - - + + - -
T2 ++ - + - - -
Patient5 T1 ++ ++ + ++ + +
T2 ++ + + ++ ++ +
Synchronous tumors with same histological types Patient1 T1 + ++ + ++ + +
T2 + + + ++ - -
Patient2 T1 ++ + + + ++ +
T2 + - + + - -
Patient3 T1 ++ ++ + ++ ++ +
T2 ++ ++ + ++ ++ -
Patient4 T1 ++ - + - - -
T2 - - + ++ - -
Patient5 T1 + + + + - -
T2 + + - + ++ +
Patient6 T1 + +++ + + - -
T2 + + + - - -
Patient7 T1 - ++ + + - -
T2 - - + + - -
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Table 2 Microsatellite marker of all tumors (Continued)
Patient8 T1 + + + + - -
T2 + - + - - -
T1 refers to the first neoplasm; T2 refers to the second neoplasm; + indicates number of alleles amplified; - indicates a lack of allele amplification.
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lar evidence suggests that the Patient 3 and 7 likely rep-
resent metastasis cancers, rather than solitary primary
tumors. However, this conclusion is made with less con-
fidence when the numbers of discordant changes are this
few.
Discussion
When patients present with multiple, morphologically
similar lung cancer, it can be impossible to distinguish
whether the neoplasms are clonally related (reflecting
metastatic disease) or clonally unrelated (representing
multiple primary cancer).
According to current histopathologic criteria, only
dual tumors with different histology or in different or-
gans will be diagnosed as multiple primary lung cancer.
The problems with this in clinical setting includes: (1)
all the tumors with consistent histopathology are diag-
nosed as metastatic cancer, but tumors with different ge-
notypes should be actually diagnosed as multiple cancer;
(2) synchronous lung tumors in one or different lobes
are simply defined as satellite lesion (T4) or metastatic
lesion (M1); (3)when the interval between the first
and the second tumor is ≤ 2 years, metachronous
multiple primary lung cancer with consistent histology is
recommended to be diagnosed as metastatic cancer;
when the interval is > 4 years, it is to be diagnosed as
multiple cancer; and when the interval is > 2 years andFigure 1 Molecular analysis of Patient 6 from primary and
metastatic tumors group. Representative results of microsatellite
PCR analysis of DNA from the neoplasms associated with Patient 6.
T1 refers to the primary lung cancer and T2 refers to the metastatic
tumor. The identity of each microsatellite marker analyzed
is indicated.≤ 4 years, its diagnosis is still inconclusive; (4) even when
histology of two tumors is different, the possibility of
metastatic or recurrent tumors cannot be excluded given
consideration to the heterogeneity of tumors; and (5)
the differential diagnosis of intrapulmonary metastatic
lung cancer (via bloodstream dissemination) verse pri-
mary lung cancer is also perplexing in clinical setting;
however, tumors with consistent histology, and N2 and
N3 lymph nodes or multiple-organ metastasis and those
with consistent histology and < 2 years interval are often
diagnosed as intrapulmonary metastasis [6]. A critical
problem is that surgical treatment is a first-choice and
effective strategy for multiple primary lung cancer, with
a treatment efficacy comparable to that in first primary
cancer; but in current clinical setting, the second tumor
will usually be diagnosed and treated as metastatic can-
cer based on radiology, as a result, patients with multiple
primary lung cancer lose the opportunity for surgical
and other proper treatments. At the same time, it is
difficult to obtain the specimens (or the specimens were
not harvested at all) for histological classification. Such
misdiagnosis poses huge damage on the patients, both
physically and mentally, and probably in a fatal way.
Therefore, one way to tackle this predicament is to ex-
plore new practical techniques and markers to diagnose
and prognosis for multiple primary lung cancers.
The exact pathogenic mechanism of multiple primary
lung cancer is still unclear, but for the time being, field
cancerization is one important hypothesis to explain theFigure 2 Molecular analysis of Patient 3 from synchronous lung
tumor with different histological types group. T1 refers to the
lung cancer of adenocarcinoma and T2 refers to the lung cancer of
squamous carcinoma. The identity of each microsatellite marker
analyzed is indicated.
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According to the hypothesis, the organ systems exposed
to the same carcinogen have increased chance for devel-
oping malignant tumors [19]. Examples are synchronous
lung cancers, head-and-neck cancer or bladder cancer,
because smoking as a carcinogen has important role in
the etiology of these malignant tumors [20]. Haraguchi
et al. [21] demonstrated in their study that multiple pri-
mary lung cancers tended to be inherited in family; lung
cancer patients with family history had higher chance
for a second or third primary tumor than those without
family history. Latest studies found that genomic in-
stability and changes in gene expression profile (such as
tumor suppressor genes and DNA repairing genes [19])
and even mutation and deletion of chromosomes were
closely related to the occurrence of multiple primary
cancers. Analysis of primary lung tumors and their
corresponding metastases revealed identical point muta-
tions affecting p53 in the tumor/metastases pairs in 73%
of the cases, suggesting that mutation of p53 is an early
event that is essential for tumorigenesis and conserved
during progression to metastatic disease [22-24]. These
studies from the literature provide strong evidence based
upon p53 mutation status that many second neoplasms
of the aerodigestive tract arise independently and there-
fore represent multiple primary tumors affecting an indi-
vidual patient. However, the methodology employed
(based upon characterization of p53 mutation status) is
not practical for broad application in the molecular diag-
nostic evaluation of patients with multiple neoplasms.
Practical molecular testing of patients affected by mul-
tiple neoplasms requires a method that is less time-
consuming and less expensive. Other methods have been
applied to this problem, including determination of
tumor relatedness through analysis of allelic loss of het-
erozygosity (LOH). Froio et al. [25] labeled and analyzed
the LOHs of the 40 chromosomes in a patient with three
synchronous multiple primary cancers and found differ-
ent genetic labels for three tumors, suggesting that three
tumors were independent on each other and that genetic
markers were useful in diagnosing multiple cancers.
While this approach is effective in the identification of
molecular differences between tumors, it requires the
presence of normal tissue for complete analysis [26].
This is problematic since germline DNA or normal
(non-neoplastic) tissue may not always be available for
analysis, especially when a tumor biopsy is collected and
analyzed. For this reason, development of a molecular
diagnostic test that relies solely on the collection of
tumor tissue from either a biopsy or needle aspirate will
prove to be more practical in a clinical setting.
Mercer et al. [8] conducted a study on lung metastatic
carcinoma from head-and-neck squamous cell carcin-
oma and primary lung carcinoma. They refined amolecular method to analyze multiple tumors that does
not rely on collection of normal tissue, can be performed
with minimal tumor sample, and will complement clin-
ical criteria for diagnostic discrimination between mul-
tiple primary cancer versus solitary metastatic disease.
At last, they found that detections of microsatellite alter-
ations and deletion sites in tumor cell DNA could be
used as diagnostic and prognostic markers for multiple
cancers.
In our study, we wanted to discriminate and analyse
the characteristic of multiple synchronous lung cancers
and metastatic lung cancers that without relying on col-
lection of normal tissure. We collected 46 specimens of
primary pulmonary synchronous tumors and metastatic
tumors and compared the genetic profiles of them.
Results from the metastatic tumors serve to validate
that clonal tumor cells have similar profiles. As the con-
sequences showed of all the patients in our study, espe-
cially in patient 1, 6 and 7, alleles corresponding to
microsatellite markers D2S1363, D6S1056, D7S1824,
D10S1239, D15S822, and D22S689 were detected in
DNA from primary tumors, but were reduced or not ob-
served in DNA from metastatic tumors. The characteris-
tic of this “unique trend” is representative in our study.
The next groups of tumors we studied were synchron-
ous tumors with different histological types of the lung.
Among the five synchronous pulmonary tumors, they
represent true synchronous tumors according to the
clinical decision rule of Martini N and Melamed MR
[18]. The result showed a “contradictory trend” compar-
ing with the first study group. The paired tumors in
cases 3 appeared to be typical of the five patients. The
observed allelic variation at D2S1363 and D7S1824 sug-
gest that T2 could be derived from T1, consistent with
metastatic disease. However, the allelic variation of
D6S1056 and D10S1239 were noted in T2 but not ob-
served in T1, which means that T1 could be also derived
from T2, so that the result contradicts the possible
lineage relationship of metastatic disease.
Among the eight synchronous tumors with same
histological types of the lung, the results of cases 4 and
5 present typical “contradictory trend” and were similar
to the synchronous lung tumor with different histo-
logical types. It suggests that the synchronous lung
tumors in this patient are not related and represent
multiple primary tumors. However, the controversial
conquences happened in patient 1, 2, 3, 6, 7 and 8.
According to the Martini N and Melamed MR [18], all
of these six patients were synchronous lung cancers.
Withing the result of this study, however, the analysis
of them showed reverse. As the result showed before,
Patient 2 provided a clear example of a patient with
clonally-related tumors, where the evidence suggest that
the T1 metastasized to the T2. In this case, microsatellite
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were detected in DNA from T1, but these markers were
not found in DNA from T2. The “trend” was similar
to the group of primary and metastatic tumors which
was considered as intrapulmonary metastasis. The obser-
vations of patient 6 and 8 were also representing
intrapulmonary metastasis, based upon the “trend”. The
molecular evidence suggests that the Patient 3 and 7 in
this group likely represent metastasis cancers, rather
than solitary primary tumors. However, this conclusion
is made with less confidence when the numbers of
discordant changes are this few.
Conclusion
The results presented in this study demonstrate that
molecular analysis of allelic variations at polymorphic
microsatellite markers can be used to determine lineage
relationships between multiple tumors, facilitating the
discrimination of second primary cancer versus meta-
static disease. This approach is rapid and sensitive. For
each of the patients diagnosed as multiple lung cancers,
especially in the patients with the same histological type,
it was impossible to determine an appropriate diagnosis
of multiple primary cancer versus metastatic disease
based solely on the traditional histopathological evalu-
ation of their tumors. Performance of a comparative
PCR-based molecular diagnostic test requires that DNA
samples corresponding to the first cancer be retrieved
for analysis along with the subsequently arising tumor
(or tumors). Thus, it is paramount that such a test be
amenable to the utilization of DNA samples from
formalin-fixed paraffin-embedded tissues since these
may be the only available source of DNA for the prior
cancer. At last, with polymorphic microsatellite markers,
the “unique trend” that represents metastasis cancers
and the “contradictory trend” that represents primary
multiple tumors are useful in the diagnosis between
tumors found at the same time in the pulmonary even
diagnosed with the histopathological evaluation. Precise
determination of the clonal origin of multiple lung
tumors might help rationalize treatment strategy and
hopefully might improve prognosis of the affected
patients.
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